Home › Encyclopedia › GHRP-1: Research Status, Identity, and Trial Data
Research / Unapproved

GHRP-1: Research Status, Identity, and Trial Data

Molecular formulaC51H62N12O7
Molecular weight955.1 g/mol
Registered trials1
PubChem CID10350910

GHRP-1 is sometimes discussed online as a growth hormone releasing peptide, but it has no approved medical use. Anyone researching it should understand what is actually known versus assumed.

Key takeaways

  • GHRP-1 is an unapproved research compound with no FDA-approved label or indication.
  • It has the molecular formula C51H62N12O7 and a molecular weight of about 955.1 g/mol.
  • One registered clinical trial involving GHRP-1 has been identified, and it was terminated.
  • No adverse event report data is currently available for this compound.

What GHRP-1 is

GHRP-1 is a synthetic peptide compound identified by PubChem CID 10350910. It has not been evaluated or approved by any regulatory agency for human therapeutic use, and no official drug label exists for it. Any claims about its biological effects in humans should be treated as unverified absent an approved label.

Clinical trial footprint

Only one clinical trial referencing GHRP-1 appears in the registered trial record reviewed here. That trial, NCT00381602, was a Phase 2, randomized, cross-over, vehicle-controlled, double-blind, multicenter study examining safety, pharmacodynamics, and preliminary efficacy of GHRP-1/AG in subjects with end-stage renal disease on hemodialysis. The trial's status is listed as terminated, meaning it did not run to completion as planned.

FAQ

Is GHRP-1 FDA approved?
No. GHRP-1 has no FDA-approved label, indication, or brand name. It remains an unapproved research compound.
What is GHRP-1's chemical makeup?
GHRP-1 has the molecular formula C51H62N12O7 and a molecular weight of approximately 955.1 g/mol. It is cataloged in PubChem under CID 10350910.
Has GHRP-1 been studied in clinical trials?
One registered clinical trial involving GHRP-1 has been identified, a Phase 2 study in hemodialysis patients with end-stage renal disease. That trial was terminated before completion.
Are there known side effects of GHRP-1?
No adverse event report data is currently available for GHRP-1, so no side effect pattern can be summarized at this time.
Why was the GHRP-1 clinical trial terminated?
The available data indicates the trial status as terminated but does not specify the reason. The study was a randomized, cross-over, vehicle-controlled, double-blind, multicenter design.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 10350910 ClinicalTrials.gov NCT00381602

Updated 2026-11-07